Several studies have demonstrated that blocking IL-1β or TNF-α or using IL-17-deficient mice markedly attenuates the colonic inflammation and development of colorectal cancer 42-44, indicating that these cytokines are the key factors responsible for the local inflammation. Here, IL17A is linked to colorectal cancer.